Author (organization)	Slides
Dr. Christine Garnett (Silver Spring, CDER, FDA)	CSRC White Paper: QT/QTc evaluation for drugs with autonomic effects
Dr. Mark Haigney (Uniform Services University Health, MD):	QT variability and drug safety
Dr. Marek Malik (London University, UK):	QT measurements and heart rate corrections
Dr. Richard Verrier (Harvard University, MA):	T-wave alternans and Drug Safety
Dr. Wojciech Zareba (University of Rochester, NY):	Repolarization Morphology and Cardiac Safety
Dr. Fabio Badilini (AMPS, NY, USA):	Optimized ECG extractions in clinical trials
Dr. Anthony Fossa (iCardiac Technologies, NY, USA):	Prospective Evaluation of advanced ECG/Holter markers to differentially assess the QT Interval with drugs that affect autonomic state vs. impair repolarization
Dr. Adel Nada (Abbott, IL, USA):	Thew Initiative: A valuable resource to large pharmaceutical company in managing cardiac safety in clinical development
Dr. Jeremy Rice (IBM, NY, USA):	Combination in vitro and in silico methodology for risk assessment of Long QT type 1 patients
Dr. Larry Satin (Cardiocore, MD, USA):	The Value of Holter Arrhythmia Analysis in Thorough QT Trials
Dr. JP Couderc (THEW)	2009 THEW Update

[12/16/2009]: The Director of the THEW interviewed by Technology Review published by the MIT: here.

[11/11/2009]: New Research Center to Focus on Cardiac Safety and Innovation in Pharmaceutical Industry Today: here.

[6/11/2009]: University of of Rochester and FDA Partner for ECG Database, Drug Discovery & Development Magazine. More info here

[5/6/2009] FDA website Existing Partnerships FDA’s Public-Private Partnership Program: THEW

[03/28/2009] Public and Private part- nership to help determine Clinical Biomarker Utility in Applied Clinical Trials online.com.>here

[7/26/2010] Members: Angel Medical System Inc. has joined the THEW initiative. Angel Medical Systems develops and markets cardiac devices that provide heart monitoring, alerting, and data collection. Their AngelMed Guardian system is an iimplantable cardiac monitoring and alerting system that is designed to warn cardiac patients of potentially life-threatening heart conditions.

 

[7/12/2010] The THEW quoted in a recent issue of the Journal of the American College of Cardiology. In a reply to a correspondence from Dr. Verrier and Nieminen on the role of T-wave alternans in hospital monitoring for torsades de pointes, Dr. Drew quoted the THEW as " a less expensive (than prospective clinical trials) and immediate available research strategy ... to validate ECG monitoring algorithms." JACC Vol. 56, No 3., 23010, 238-42.

 

[1/13/2010] Members: The Oxford University Computing Laboratory is the first new member for year 2010. At the heart of computing and related interdisciplinary activity at Oxford, this centre focuses on research in computer science, numerical analysis, computational biology, quantum computation, computational linguistics, and information systems. The Computational Biology Group also plays a key role in interdisciplinary initiatives across the University, including the EU FP7 projects euHeart and PreDiCT.